HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides
HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides
复制标题
用重组牛痘病毒和合成肽定义的 HIV-1 gag 特异性细胞毒性 T 淋巴细胞
作者：
D. Nixon;A. Townsend;J. Elvin;C. Rizza;J. Gallwey;A. McMichael
目前的候选疫苗在存在抗体应答的情况下不能保护灵长类动物免受人类免疫缺陷病毒（HIV）的攻击1；这强调了研究细胞介导的HIV免疫和鉴定刺激细胞毒性T淋巴细胞（CTL）的特异性表位的重要性。利用重组痘苗病毒表达HIV-1的gag蛋白，我们在15例健康的HIV血清阳性患者中发现13例HLA - i类限制性gag特异性CTL。然后我们在裂解实验中使用短合成肽2 - 5筛选gag CTL表位。在一名患者中，我们已经鉴定出p24中的肽，该肽与HLA-B27相关，可被CTL识别。这种肽，以及通过这些方法确定的其他肽序列，可以被纳入设计用于诱导细胞介导的抗HIV免疫的疫苗中。
Current candidate vaccines fail to protect primates against challenge with human immunodeficiency virus (HIV) in the presence of antibody responses1; this underlines the importance of studying cell-mediated immunity to HIV and identifying specific epitopes that stimulate cytotoxic T lymphocytes (CTL). Using a recombinant vaccinia virus to express the gag protein of HIV-1 we found HLA class-I-restricted gag-specific CTL in thirteen out of fifteen healthy HIV seropositive patients. We then used short synthetic peptides in the lysis assay2–5 to screen for gag CTL epitopes. In one patient we have identified a peptide in p24 that is recognized by CTL in association with HLA-B27. This peptide, and further peptide sequences defined by these methods, could be incorporated in vaccines designed to induce cell-mediated immunity against HIV.